Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Shandong Weigao Group Medical Polymer Co Ltd
Accounts Receivables
Shandong Weigao Group Medical Polymer Co Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Accounts Receivables
¥7.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
S
|
Shanghai Conant Optical Co Ltd
HKEX:2276
|
Accounts Receivables
¥250.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Accounts Receivables
¥1.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Accounts Receivables
¥980.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Accounts Receivables
¥950.1m
|
CAGR 3-Years
51%
|
CAGR 5-Years
33%
|
CAGR 10-Years
26%
|
|
|
Intco Medical Technology Co Ltd
SZSE:300677
|
Accounts Receivables
¥1.4B
|
CAGR 3-Years
34%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
Shandong Weigao Group Medical Polymer Co Ltd
Glance View
Nestled in the bustling industrial heart of China, Shandong Weigao Group Medical Polymer Co Ltd stands as a testament to the transformative potential within the field of medical devices. Since its inception in 1988, Weigao has diligently carved out a niche within the healthcare sector, specializing in the production and distribution of medical consumables, orthopedic materials, and blood purification apparatus. The company's journey is intertwined with China's healthcare evolution, as it became a critical player in supplying hospitals and medical institutions with essential, reliable tools. By leveraging advancements in polymer science, Weigao consistently pushes the boundaries in creating high-quality, cost-effective products—a maneuver that not only reduces healthcare costs but also ensures widespread accessibility to essential medical supplies. Driven by an intricate understanding of the medical landscape, Weigao's operational model hinges on its robust vertical integration strategy. The company effectively controls every stage of its production process, from raw material procurement to product manufacturing and distribution. This control not only ensures stringent quality checks but also allows for improved economies of scale, thereby boosting its profitability margins. Revenue streams largely stem from its extensive product lineup, which includes syringes, blood bags, infusion sets, and orthopedic devices, catering to domestic demand while also penetrating international markets. The constant stream of innovations, coupled with an expanding global footprint, underscores Weigao's commitment to growth, firmly positioning it as a stalwart in the medical apparatus industry.
See Also
What is Shandong Weigao Group Medical Polymer Co Ltd's Accounts Receivables?
Accounts Receivables
7.8B
CNY
Based on the financial report for Dec 31, 2025, Shandong Weigao Group Medical Polymer Co Ltd's Accounts Receivables amounts to 7.8B CNY.
What is Shandong Weigao Group Medical Polymer Co Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
11%
Over the last year, the Accounts Receivables growth was 29%. The average annual Accounts Receivables growth rates for Shandong Weigao Group Medical Polymer Co Ltd have been 13% over the past three years , 11% over the past five years .